Zion Oil & Gas (ZNOG) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Document Information Line Items
Entity Registrant Name	ZION OIL & GAS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		340,521,048
Amendment Flag	false
Entity Central Index Key	0001131312
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0065053
Entity Address, Address Line One	12655 N Central Expressway
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75243
City Area Code	(214)
Local Phone Number	221-4610
Entity Interactive Data Current	Yes
Entity File Number	001-33228

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 4,564	$ 11,708
Fixed short term bank and escrow deposits – restricted	1,269	2,954
Prepaid expenses and other	473	1,900
Other deposits	595	597
Governmental receivables	1,770	2,040
Other receivables	379	195
Total current assets	9,050	19,394
Unproved oil and gas properties, full cost method (see Note 4)	39,439	15,526
Property and equipment at cost
Drilling rig and related equipment, net of accumulated depreciation of $525 and nil (see note 2J)	6,948	7,568
Property and equipment, net of accumulated depreciation of $595 and $564	146	131
Property and equipment at cost	7,094	7,699
Right of Use Lease Assets (see Note 7)	390	438
Other assets
Assets held for severance benefits	503	446
Total other assets	503	446
Total assets	56,476	43,503
Current liabilities
Accounts payable	2,212	1,369
Lease obligation – current (see Note 7)	228	191
Asset retirement obligation	571	571
Derivative liability (see Note 6)		431
10% Senior convertible bonds, net of unamortized deferred financing cost of nil and $9 and unamortized debt discount of nil and $205 at September 30, 2021 and December 31, 2020, respectively (see Note 5)		3,033
Accrued liabilities	1,638	1,987
Total current liabilities	4,649	7,582
Long-term liabilities
Lease obligation – non-current (see Note 7)	200	307
Provision for severance pay	517	505
Total long-term liabilities	717	812
Total liabilities	5,366	8,394
Commitments and contingencies (see Note 8)
Stockholders’ equity
Common stock, par value $.01; Authorized: 800,000,000 shares at September 30, 2021: Issued and outstanding: 304,260,077 and 237,381,555 shares at September 30, 2021 and December 31, 2020, respectively	3,043	2,374
Additional paid-in capital	269,790	245,539
Accumulated deficit	(221,723)	(212,804)
Total stockholders’ equity	51,110	35,109
Total liabilities and stockholders’ equity	$ 56,476	$ 43,503

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accumulated depreciation of drilling rig and related equipment	$ 525
Accumulated depreciation of property and equipment	595	564
Unamortized deferred financing cost current, net		9
Unamortized debt discount current		$ 205
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in Shares)	800,000,000	800,000,000
Common stock, issued (in Shares)	304,260,077	237,381,555
Common stock, outstanding (in Shares)	304,260,077	237,381,555

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
General and administrative	$ 1,601	$ 1,139	$ 6,524	$ 3,227
Other	697	563	2,553	1,608
Loss from operations	(2,298)	(1,702)	(9,077)	(4,835)
Other income (expense), net
Gain (loss) on derivative liability		49	431	(2)
Foreign exchange gain (loss)	7	(4)	(43)	(7)
Financial expenses, net	(12)	(139)	(230)	(484)
Loss, before income taxes	(2,303)	(1,796)	(8,919)	(5,328)
Income taxes
Net loss	$ (2,303)	$ (1,796)	$ (8,919)	$ (5,328)
Net (loss), gain per share of common stock
Basic and diluted (in US$) (in Dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted-average shares outstanding
Basic and diluted (in thousands) (in Shares)	286,390	202,877	258,442	171,296

Consolidated Condensed Statem_2

Consolidated Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock		Additional paid-in Capital	Accumulated deficit	Total
Balance at Dec. 31, 2019	$ 1,240		$ 217,892	$ (205,808)	$ 13,324
Balance (in Shares) at Dec. 31, 2019	123,973
Funds received from sale of DSPP units and shares and exercise of warrants	$ 1,053		24,464		25,517
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	105,354
Value of bonds converted to shares
Value of bonds converted to shares (in Shares)	1
Bond interest paid in shares	$ 18		307		325
Bond interest paid in shares (in Shares)	1,782
Funds received from option exercises	$ 7				7
Funds received from option exercises (in Shares)	653
Value of options granted to employees, directors and others as non-cash compensation			59		59
Net loss				(5,328)	(5,328)
Balance at Sep. 30, 2020	$ 2,318		242,722	(211,136)	33,904
Balance (in Shares) at Sep. 30, 2020	231,763
Balance at Jun. 30, 2020	$ 1,799		230,220	(209,340)	22,679
Balance (in Shares) at Jun. 30, 2020	179,909
Funds received from sale of DSPP units and shares and exercise of warrants	$ 516		12,499		13,015
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	51,589
Funds received from option exercises	$ 3				3
Funds received from option exercises (in Shares)	265
Value of options granted to employees, directors and others as non-cash compensation			3		3
Net loss				(1,796)	(1,796)
Balance at Sep. 30, 2020	$ 2,318		242,722	(211,136)	33,904
Balance (in Shares) at Sep. 30, 2020	231,763
Balance at Dec. 31, 2020	$ 2,374		245,539	(212,804)	35,109
Balance (in Shares) at Dec. 31, 2020	237,382
Funds received from sale of DSPP units and shares and exercise of warrants	$ 607		17,550		18,157
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	60,665
Costs associated with the issuance of shares			(115)		(115)
Value of bonds converted to shares		[1]	9		9
Value of bonds converted to shares (in Shares)	15
Bond interest paid in shares	$ 5		316		321
Bond interest paid in shares (in Shares)	530
Bond principal paid in shares	$ 53		3,161		3,214
Bond principal paid in shares (in Shares)	5,296
Funds received from option exercises	$ 4		11		15
Funds received from option exercises (in Shares)	372
Value of options granted to employees, directors and others as non-cash compensation			3,319		3,319
Net loss				(8,919)	(8,919)
Balance at Sep. 30, 2021	$ 3,043		269,790	(221,723)	51,110
Balance (in Shares) at Sep. 30, 2021	304,260
Balance at Jun. 30, 2021	$ 2,833		264,887	(219,420)	48,300
Balance (in Shares) at Jun. 30, 2021	283,273
Funds received from sale of DSPP units and shares and exercise of warrants	$ 207		4,162		4,369
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	20,732
Funds received from option exercises	$ 3		11		14
Funds received from option exercises (in Shares)	255
Value of options granted to employees, directors and others as non-cash compensation			730		730
Net loss				(2,303)	(2,303)
Balance at Sep. 30, 2021	$ 3,043		$ 269,790	$ (221,723)	$ 51,110
Balance (in Shares) at Sep. 30, 2021	304,260
[1]	Less than one thousand.

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (8,919)	$ (5,328)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	556	36
Cost of options issued to employees, directors and others as non-cash compensation	3,319	59
Amortization of debt discount related to convertible bonds	190	332
Non-cash interest expense		101
Change in derivative liability	(431)	2
Change in assets and liabilities, net:
Other deposits	2	(361)
Prepaid expenses and other	1,427	(106)
Governmental receivables	270	25
Lease obligation – current	(91)	(32)
Lease obligation – noncurrent	(107)	(143)
Right of use lease assets	176	158
Other receivables	(184)	191
Severance payable, net	(45)	28
Accounts payable	(291)	31
Asset retirement obligation		(14)
Accrued liabilities	(760)	(125)
Net cash used in operating activities	(4,888)	(5,146)
Cash flows from investing activities
Acquisition of property and equipment	(46)	(9)
Acquisition of drilling rig and related equipment	(115)	(4,636)
Investment in unproved oil and gas properties	(21,837)	(880)
Net cash used in investing activities	(21,998)	(5,525)
Cash flows from financing activities
Payments related to capital lease		(9)
Costs paid related to the issuance of new shares	(115)
Proceeds from exercise of stock options	15	7
Proceeds from issuance of stock and exercise of warrants	18,157	25,517
Net cash provided by financing activities	18,057	25,515
Net increase in cash, cash equivalents and restricted cash	(8,829)	14,844
Cash, cash equivalents and restricted cash – beginning of period	14,662	5,935
Cash, cash equivalents and restricted cash – end of period	5,833	20,779
Supplemental schedule of cash flow information
Cash paid for interest		2
Non-cash investing and financing activities:
Convertible Bond interest paid in shares	321	325
Convertible Bond principal paid in shares	3,214
Unpaid investments in oil & gas properties	3,114	183
10% Senior Convertible Bonds converted to shares	9		[1]
Capitalized convertible bond interest attributed to oil and gas properties	104	$ 110
New lease accounted for as a right of use lease asset	$ 128
[1]	Less than one thousand

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Cash and cash equivalents	$ 4,564	$ 11,708	$ 18,621	$ 4,845
Restricted cash included in fixed short-term bank deposits	1,269	2,954	2,158	1,090
Total cash, cash equivalents and restricted cash	$ 5,833	$ 14,662	$ 20,779	$ 5,935

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Going Concern	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Nature of Operations, Basis of Presentation and Going Concern	Note 1 - Nature of Operations, Basis of Presentation and Going Concern A. Nature of Operations Zion Oil & Gas, Inc., a Delaware corporation (“we,” “our,” “Zion” or the “Company”) is an oil and gas exploration company with a history of 21 years of oil & gas exploration in Israel. As of September 30, 2021, the Company has no revenues from its oil and gas operations. Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company’s operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company. On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts in the future, and on January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect. Zion has the trademark “ZION DRILLING” filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel. Exploration Rights/Exploration Activities The Company currently holds one active petroleum exploration license onshore Israel, the New Megiddo License 428 (“NML 428”), comprising approximately 99,000 acres. The NML 428 was awarded on December 3, 2020 for a six-month term with the possibility of an additional six-month extension. On April 29, 2021, Zion submitted a request to the Ministry of Energy for a six-month extension to December 2, 2021. On May 30, 2021, the Ministry of Energy approved our request for extension to December 2, 2021. The ML 428 lies onshore, south and west of the Sea of Galilee and we continue our exploration focus here as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential. The Megiddo Jezreel #1 (“MJ #1”) exploratory well was spud on June 5, 2017 and drilled to a total depth (“TD”) of 5,060 meters (approximately 16,600 feet). Thereafter, the Company successfully cased and cemented the well while awaiting the approval of the testing protocol. The Ministry of Energy approved the well testing protocol on April 29, 2018. During the fourth quarter of 2018, the Company testing protocol was concluded at the MJ #1 well. The test results confirmed that the MJ #1 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2018, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of $30,906,000. During the nine months ended September 30, 2021, and 2020, respectively, the Company did not record any post-impairment charges. The MJ#1 well provided Zion with information Zion believes is important for potential future exploration efforts within its license area. As with many frontier wildcat wells, the MJ#1 also left several questions unanswered. While not meant to be an exhaustive list, a summary of what Zion believes to be key information learned in the MJ#1 well is as follows: 1. The MJ#1 encountered much higher subsurface temperatures at a depth shallower than expected before drilling the well. In our opinion, this is significant because reaching a minimum temperature threshold is necessary for the generation of hydrocarbons from an organic-rich source rock. 2. The known organic rich (potentially hydrocarbon bearing) Senonian age source rocks that are typically present in this part of Israel were not encountered as expected. Zion expected these source rocks to be encountered at approximately 1,000 meters in the MJ#1 well. 3. MJ#1 had natural fractures, permeability (the ability of fluid to move through the rock) and porosity (pore space in rock) that allowed the sustained flow of formation fluid in the shallower Jurassic and lower Cretaceous age formations between approximately 1,200 and 1,800 meters. While no hydrocarbons were encountered, Zion believes this fact is nonetheless significant because it provides important information about possible reservoir pressures and the ability of fluids to move within the formation and to the surface. 4. MJ#1 encountered oil in the Triassic Mohilla formation which Zion believes may indicate the presence of an active deep petroleum system is in Zion’s license area. There did not appear to be any natural permeability or porosity in the Triassic Mohilla formation to allow formation fluid to reach the surface naturally during testing, and thus the MJ#1 was not producible or commercial 5. The depths and thickness of the formations we encountered varied greatly from pre-drill estimates. This required the MJ#1 to be drilled to a much greater depth than previously expected. Zion has tied these revised formation depths to seismic data which will allow for more accurate interpretation and mapping in the future. A summary of what Zion believes to be some key questions left to be answered are: 1. Is the missing shallow Senonian age source rock a result of regional erosion, or is it missing because of a fault that cut the well-bore and could be reasonably expected to be encountered in the vicinity of the MJ#1 drill site? Zion believes this is an important question to answer because if the Senonian source rocks do exist in this area, the high temperatures encountered are sufficient to mature these source rocks and generate oil. 2. Do the unusually high shallow subsurface temperatures extend regionally beyond the MJ#1 well, which could allow for the generation of hydrocarbons in the Senonian age source rock within our license area? 3. As a consequence of seismic remapping, where does the MJ#1 well lie relative to the potential traps at the Jurassic and Triassic levels and was the well location too low on the structures and deeper than the potential hydrocarbons within those traps? As a result of these unanswered questions and with the information gained drilling the MJ#1 well, Zion believed it was prudent and consistent with good industry practice to try and answer some of these questions with a focused 3-D seismic imaging shoot of approximately 72 square kilometers surrounding the MJ#1 well. Zion has completed all of the acquisition, processing and interpretation of the 3-D data and has incorporated its expanded knowledge base into the drilling of our current MJ-02 exploratory well (see further details below). Zion’s geology team is continuing to work on a larger interpretation of 3D areas, along with potential exploration locations located in the western portion of the NML 428 area. Megiddo-Jezreel Petroleum License, No. 401 (“MJL 401”) and New Megiddo License 428 (“NML 428”) The Megiddo-Jezreel License 401 was awarded on December 3, 2013 for a three-year primary term through December 2, 2016 with the possibility of additional one-year extensions up to a maximum of seven years. The Megiddo-Jezreel License 401 lies onshore, south and west of the Sea of Galilee, and we continue our exploration focus here as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential. The NML 428 was awarded on December 3, 2020 for a six-month term with the possibility of an additional six-month extension. This license effectively replaced the Megiddo-Jezreel License 401 as it has the same area and coordinates. The MJ-02 drilling plan was approved by the Ministry of Energy on July 29, 2020. On January 6, 2021, Zion officially spudded its MJ-02 exploratory well. Zion plans to reach a total depth of approximately 5,600 meters (~18,368 feet). Zion recently announced the successful casing and cementing operations in a key section of the well. The company continues making solid progress in the drilling of the MJ-02 well as it moves closer to geological targets. B. Basis of Presentation The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the year ending December 31, 2021 or for any other subsequent interim period. C. Going Concern The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons. The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The Company’s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, the Company’s ability to continue as a going concern may be impaired. The consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the nine months ended September 30, 2021, the Company incurred a net loss of approximately $8.9 million and had an accumulated deficit of approximately $221.7 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern. To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies A. Net Gain (Loss) per Share Data Basic and diluted net (loss) gain per share of common stock, par value $0.01 per share (“Common Stock”), is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share, as the inclusion of 21,810,891 and 17,471,772 and 10,219,066 and 10,404,146 Common Stock equivalents in the three- and nine-month period ended September 30, 2021 and 2020 respectively, would be anti-dilutive. B. Use of Estimates The preparation of the accompanying consolidated condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates. C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the three and nine months ended September 30, 2021, and 2020, respectively, the Company did not record any post-impairment charges. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $39,439,000 and $15,526,000 as of September 30, 2021 and December 31, 2020, respectively. D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At September 30, 2021, and December 31, 2020, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. Derivative instruments are carried at fair value, generally estimated using the Binomial Model. E. Derivative Liabilities In accordance with ASC 815-40-25 and ASC 815-10-15 Derivatives and Hedging and ASC 480-10-25 Liabilities-Distinguishing Liabilities from Equity, the embedded derivatives associated with the Convertible Bonds are accounted for as a liability during the term of the related Convertible Bonds (see Note 5). F. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. G. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity H. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report, with the exception of recurring monthly consulting fees paid to certain management personnel. I. Recently Adopted Accounting Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its consolidated financial statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its unaudited consolidated condensed financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. J. Depreciation and Accounting for Drilling Rig and Inventory On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. We remitted to the Seller $250,000 on February 6, 2020 as earnest money towards the purchase price. The Closing anticipated by the Agreement took place on March 12, 2020 by the Seller’s execution and delivery of a Bill of Sale to us. On March 13, 2020, the Seller retained the earnest money deposit, and the Company remitted $4,350,000 to the seller towards the purchase price and $1,000,000 (the “Holdback Amount”) was deposited in escrow with American Stock Transfer and Trust Company LLC, as escrow agent, through November 30, 2020, or as extended by mutual agreement of the parties, pending a determination, if any, by us of any operating deficiency in the drilling rig. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021. Since the rig was purchased and closed during March 2020, this purchase was recorded on Zion’s books as a long-term fixed asset as a component of Property and Equipment. The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion has been depreciating the rig on a straight-line basis since it was placed in service. The $540,000 in spare parts was the original cost to CED. These items were received and counted by Zion upon receipt. All records and files are maintained by Zion. Zion plans to obtain a physical count of the equipment items at the end of each quarter, or as close to such date as practical, in accordance with our normal procedures. Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account and our straight-line amortization will be adjusted accordingly. See the table below for a reconciliation of the rig-related activity during the nine months ended September 30, 2021: I-35 Drilling Rig & Associated Equipment: I-35 Drilling Rig Spare Other Drilling Total US$ US$ US$ US$ December 31, 2020 6,494 698 376 7,568 Asset Additions - 89 26 115 Asset Depreciation (475 ) - (50) (525 ) Asset Disposals for Self-Consumption - (210 ) - (210 ) September 30, 2021 6,019 577 352 6,948

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Note 3 - Stockholders’ Equity The Company’s shareholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01, that the Company is authorized to issue from 400,000,000 shares to 800,000,000 shares, effective June 9, 2021. A. 2011 Equity Incentive Stock Option Plan During the nine months ended September 30, 2021, the Company granted the following options from the 2011 Equity Incentive Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 600,000 shares of Common Stock to six senior officers and three staff members at an exercise price of $0.915 per share. The options vested upon grant and are exercisable through January 4, 2031. The fair value of the options at the date of grant amounted to approximately $456,000. ii. Options to purchase 75,000 shares of Common Stock were granted to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 6, 2031. The fair value of the options at the date of grant amounted to approximately $68,000. These options were granted per the provisions under the Israeli Appendix to the Plan. iii. Options to purchase 1,800,000 shares of Common Stock to six senior officers and three staff members at an exercise price of $0.59 per share. The options vested upon grant and are exercisable through May 21, 2031. The fair value of the options at the date of grant amounted to approximately $885,000. iv. Options to purchase 200,000 shares of Common Stock were granted to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through May 21, 2031. The fair value of the options at the date of grant amounted to approximately $117,000. These options were granted per the provisions under the Israeli Appendix to the Plan. During the nine months ended September 30, 2020, the Company granted the following options from the 2011 Equity Incentive Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 110,000 shares of Common Stock to five senior officers at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 6, 2030. The fair value of the options at the date of grant amounted to approximately $57,000. ii. Options to purchase 10,000 shares of Common Stock to one staff member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through September 1, 2030. The fair value of the options at the date of grant amounted to approximately $2,000. B. 2011 Non-Employee Directors Stock Option Plan During the nine months ended September 30, 2021, the Company granted the following qualified (market value) and non-qualified options from the 2011 Non-Employee Directors Stock Option Plan for directors to purchase shares of common stock as non-cash compensation: i. Options to purchase 350,000 shares of Common Stock to seven board members at an exercise price of $0.915 per share. The options vested upon grant and are exercisable through January 4, 2027. The fair value of the options at the date of grant amounted to approximately $252,000. ii. Options to purchase 50,000 shares of Common Stock were granted to one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2027. The fair value of the options at the date of grant amounted to approximately $45,000. These options were granted per the provisions under the Israeli Appendix to the Plan. iii. Options to purchase 1,400,000 shares of Common Stock to six board members and one consultant at an exercise price of $0.59 per share. The options vested upon grant and are exercisable through May 21, 2027. The fair value of the options at the date of grant amounted to approximately $643,000. iv. Options to purchase 200,000 shares of Common Stock were granted to one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through May 21, 2027. The fair value of the options at the date of grant amounted to approximately $116,000. These options were granted per the provisions under the Israeli Appendix to the Plan. During the nine months ended September 30, 2020, the Company did not grant any qualified (market value) options from the 2011 Non-Employee Directors Stock Option Plan to its directors. C. 2021 Incentive Stock Option Plan Effective June 9, 2021, the Company’s shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan (“Omnibus Plan”) for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock. The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions. The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant. During the nine months ended September 30, 2021, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 25,000 shares of Common Stock to one board member at an exercise price of $0.29 per share. The options vested upon grant and are exercisable through June 15, 2031. The fair value of the options at the date of grant amounted to approximately $6,000. ii. Options to purchase 1,425,000 shares of Common Stock to eleven board members and four senior officers at an exercise price of $0.39 per share. The options vested upon grant and are exercisable through July 09, 2031. The fair value of the options at the date of grant amounted to approximately $468,000. iii. Options to purchase 100,000 shares of Common Stock to seven staff members and one consultant at an exercise price of $0.39 per share. The options vested upon grant and are exercisable through July 13, 2031. The fair value of the options at the date of grant amounted to approximately $33,000. iv. Options to purchase 375,000 shares of Common Stock two board member and six staff members at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through July 17, 2031. The fair value of the options at the date of grant amounted to approximately $140,000. v. Options to purchase 10,000 shares of Common Stock to one staff member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through September 1, 2031. The fair value of the options at the date of grant amounted to approximately $2,000. vi. Options to purchase 413,000 shares of Common Stock to one board member, three senior officers and two employees at an exercise price of $0.25 per share. The options vested upon grant and are exercisable through September 1, 2031. The fair value of the options at the date of grant amounted to approximately $87,000. C. Stock Options The stock option transactions since January 1, 2021 are shown in the table below: Number of Weighted Average US$ Outstanding, December 31, 2020 3,797,750 1.14 Changes during 2021 to: Granted to employees, officers, directors and others 7,023,000 0.49 Expired/Cancelled/Forfeited (183,000 ) 1.52 Exercised (372,000 ) 0.04 Outstanding, September 30, 2021 10,265,750 0.73 Exercisable, September 30, 2021 10,265,750 0.73 The following table summarizes information about stock options outstanding as of September 30, 2021: Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number outstanding Weighted Weighted Range of Number Weighted average Weighted US$ US$ US$ US$ — — — — 0.01 10,000 2.12 0.01 — — — — 0.01 5,000 2.70 0.01 — — — — 0.01 20,000 4.67 0.01 — — — — 0.01 130,000 5.25 0.01 — — — — 0.01 50,000 5.26 0.01 — — — — 0.01 60,000 5.54 0.01 — — — — 0.01 200,000 5.63 0.01 — — — — 0.01 40,000 6.00 0.01 — — — — 0.01 87,500 6.25 0.01 — — — — 0.01 25,000 6.26 0.01 — — — — 0.01 30,000 6.41 0.01 — — — — 0.01 4,000 6.51 0.01 — — — — 0.01 25,000 7.26 0.01 — — — — 0.01 105,000 7.96 0.01 — — — — 0.01 220,000 8.13 0.01 — — — — 0.01 35,000 8.26 0.01 — — — — 0.01 75,000 9.26 0.01 — — — — 0.01 200,000 9.63 0.01 — — — — 0.01 355,000 9.79 0.01 — — — — 0.01 10,000 9.92 0.01 — — — — 0.16 340,000 4.19 0.16 — — — — 0.16 75,000 8.19 0.16 — — — — 0.18 25,000 4.17 0.18 — — — — 0.25 50,000 9.92 0.25 — — — — 0.25 363,000 9.92 0.25 — — — — 0.28 25,000 3.92 0.28 — — — — 0.28 25,000 7.92 0.28 — — — — 0.29 25,000 5.70 0.29 — — — — 0.39 1,515,000 9.77 0.39 — — — — 0.39 10,000 9.95 0.39 — — — — 0.59 1,400,000 5.63 0.59 — — — — 0.59 1,800,000 9.63 0.59 — — — — 0.92 350,000 5.26 0.92 — — — — 0.92 600,000 9.26 0.92 — — — — 1.33 25,000 1.57 1.33 — — — — 1.38 105,307 3.26 1.38 — — — — 1.55 200,000 0.68 1.55 — — — — 1.67 405,943 3.01 1.67 — — — — 1.70 218,500 1.22 1.70 — — — — 1.75 250,000 1.76 1.75 — — — — 1.78 25,000 2.93 1.78 — — — — 2.31 250,000 2.25 2.31 2.61 471,500 0.18 2.61 — — — — 4.15 25,000 2.76 4.15 0.01-4.15 10,265,750 0.73 Granted to employees The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the nine months ended 2021 2020 Weighted-average fair value of underlying stock at grant date $ 0.55 $ 0.50 Dividend yields — — Expected volatility 121%-143 % 90%-103 % Risk-free interest rates 0.16%-0.85 % 0.26%-1.61 % Expected lives (in years) 3.00-5.00 5.00 Weighted-average grant date fair value $ 0.47 $ 0.49 Granted to non-employees The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the nine months ended 2021 2020 Weighted-average fair value of underlying stock at grant date $ 0.58 $ — Dividend yields — — Expected volatility 100%-113 % — Risk-free interest rates 1.07%-1.42 % — Expected lives (in years) 6.00-10.00 — Weighted-average grant date fair value $ 0.49 $ — The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options. The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 (“SAB 110”), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life. D. Compensation Cost for Warrant and Option Issuances The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors: For the three months ended September 30, 2021 2020 US$ thousands US$ thousands 727 3 For the nine months ended September 30, 2021 2020 US$ thousands US$ thousands 3,217 59 The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees: For the three months ended September 30, 2021 2020 US$ thousands US$ thousands 3 — For the nine months ended September 30, 2021 2020 US$ thousands US$ thousands 102 — The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: For the three months ended September 30, 2021 2020 US$ thousands US$ thousands — — For the nine months ended September 30, 2021 2020 US$ thousands US$ thousands — — E. Dividend Reinvestment and Stock Purchase Plan (“DSPP”) On March 13, 2014 Zion filed a registration statement on Form S-3 that is part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three-year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336. On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the “DSPP” or the “Plan”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended. The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00. As of May 2, 2017, any outstanding ZNWAB warrants expired. As of May 2, 2018, any outstanding ZNWAC warrants expired. On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.” The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advance notice to the warrant holders. On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit program terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.” All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advance notice to the warrant holders. An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017. Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.” The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2023 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advance notice to the warrant holders. On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.” The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.” The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.” The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this unit offering. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.” The warrants became exercisable on August 26, 2019 and continue to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit program consisting of Units (shares of stock and warrants) to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant has the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2022 at a per share exercise price of $1.00. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.” Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continue to be exercisable through June 2, 2022 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued on April 4, 2022 and be exercisable through July 6, 2022 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under

Unproved Oil and Gas Properties

Unproved Oil and Gas Properties, Full Cost Method	9 Months Ended
	Sep. 30, 2021
Oil and Gas Property [Abstract]
Unproved Oil and Gas Properties, Full Cost Method	Note 4 - Unproved Oil and Gas Properties, Full Cost Method Unproved oil and gas properties, under the full cost method, are comprised as follows: September 30, December 31, US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 25,551 4,232 Capitalized salary costs 2,122 1,967 Capitalized interest costs 1,418 1,314 Legal and seismic costs, license fees and other preparation costs 10,309 7,974 Other costs 39 39 39,439 15,526 Changes in Unproved oil and gas properties during the three and nine months ended September 30, 2021 and 2020 are as follows: For the three months ended For the nine months ended 2021 2020 2021 2020 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 6,727 79 21,319 163 Capitalized salary costs 38 56 155 153 Capitalized interest costs - 51 104 110 Legal costs, license fees and other preparation costs 573 318 2,335 716 Other costs - 4 - 15 *7,338 *508 *23,913 *1,157 * Inclusive of non-cash amounts of approximately $316,000, and $154,000 during the three months ended September 30, 2021, and 2020, respectively * Inclusive of non-cash amounts of approximately $3,218,000, and $293,000 during the nine months ended September 30, 2021, and 2020, respectively Please refer to Footnote 1 – Nature of Operations and Going Concern for more information about Zion’s exploration activities.

Senior Convertible Bonds

Senior Convertible Bonds	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Senior Convertible Bonds	Note 5 - Senior Convertible Bonds Rights Offering -10% Senior Convertible Notes due May 2, 2021 and paid on May 3, 2021 On October 21, 2015, the Company filed with the SEC a prospectus supplement for a rights offering. Under this rights offering, we distributed at no cost, 360,000 non-transferable subscription rights to subscribe for, on a per right basis, two 10% Convertible Senior Bonds par $100 due May 2, 2021 (the “Notes”), to shareholders of the Company’s Common Stock on October 15, 2015, the record date for the offering. Each whole subscription right entitled the participant to purchase two convertible bonds at a purchase price of $100 per bond. Effective October 21, 2015, the Company executed a Supplemental Indenture, as issuer, with the American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (“AST”), as trustee for the Notes (the “Indenture”). On March 31, 2016, the rights offering terminated. On May 2, 2016, the Company issued approximately $3,470,000 aggregate principal amount of convertible bonds or Notes in connection with the rights offering. The Company received net proceeds of approximately $3,334,000, from the issuance of the Notes, after deducting fees and expenses of $136,000 incurred in connection with the offering. These costs have been discounted as deferred offering costs. The Notes contained a convertible option that gave rise to a derivative liability, which was accounted for separately from the Notes (see below). Accordingly, the Notes were initially recognized at fair value of approximately $1,844,000, which represents the principal amount of $3,470,000 from which a debt discount of approximately $1,626,000 (which is equal to the fair value of the convertible option) was deducted. During the three and nine months ended September 30, 2021, the Company recorded approximately $ nil nil nil During the three and nine months ended September 30, 2020, the Company recorded approximately $7,000 and $20,000, respectively, in amortization expense related to the deferred financing costs, approximately $97,000 and $314,000, respectively, in debt discount amortization net, and approximately $0 and $3,000, respectively, related to financing gains associated with Notes converted to shares. The Notes were governed by the terms of the Indenture. The Notes were senior unsecured obligations of the Company and had an interest rate of 10% per year, payable annually in arrears on May 2 of each year, commencing May 2, 2017. The Notes matured on May 2, 2021, and the annual interest and principal were paid on May 3, 2021 (see below). Interest and principal may be paid, at the Company’s option, in cash or in shares of the Company’s Common Stock. The number of shares for the payment of interest in shares of Common Stock, in lieu of the cash amount, will be based on the average of the closing prices of the Company’s Common Stock as reported by Bloomberg L.P. for the 30 trading days preceding the record date for the payment of interest; such record date has been designated and will always be the 10 th On April 2, 2021, the ability of bondholders to convert the bonds ended so the 30-day average share price could be computed. On May 2, 2021, Zion’s bonds expired. Zion chose to pay the principal in kind with our stock. On May 2, 2021, a total of 32,139 $100 face value bonds were outstanding. The 30-day moving average price used to settle the bonds was $.606. Zion settled the principal on the bonds by issuing approximately 5,300,000 shares of our common stock. The annual 10% coupon payment was paid in shares using the same 30-day average price. Zion issued approximately 530,000 shares for the remaining bond holders’ interest payment. On May 3, 2021, the Company paid its annual 10% interest to its bondholders of record on April 20, 2021. The interest was paid-in-kind (“PIK”) in the form of Common Stock. An average of the Company stock price of $.606 was determined based on the 30 trading days prior to the record date of April 20, 2021. This figure was used to divide into 10% of the par value of the bonds held by the holders. The Company issued approximately 530,000 shares to the accounts of its bondholders. Additionally, on May 3, 2021, the Company issued approximately 5,300,000 shares to the accounts of its bondholders in payment of the principal amount of the convertible bonds. As of the date of this report, the Company fully paid its annual interest over the course of five years, as well as the principal amount of the bonds, and its obligation is completed. Through the three and nine months ended September 30, 2021, nil nil Through the three and nine months ended September 30, 2020, 0 and 28 convertible bonds of $100 each, respectively, have been converted at a conversion rate of approximately $2.27 per share. As a result, the Company issued approximately 0 and 1,232 shares of its Common Stock during the same period, respectively, and recorded approximately $ nil September 30, December 31, US$ US$ 10% Senior Convertible Bonds, on the day of issuance $ - $ 3,470 Unamortized Debt discount, net $ - $ (205 ) Bonds converted to shares $ - $ (223 ) Offering cost, net $ - $ (9 ) 10% senior Convertible bond - Liability $ - $ 3,033 Capitalized interest for the three and nine months ended September 30, 2021 was $ nil Interest expenses for the three and nine months ended September 30, 2021 were $ nil nil

Derivative Liability

Derivative Liability	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	Note 6 - Derivative Liability The Notes issued by the Company and discussed in Note 5 contained a convertible option that gives rise to a derivative liability. The debt instrument the Company issued included a make-whole provision, which provides that in the event of conversion by the investor under certain circumstances, the issuer is required to deliver to the holder additional consideration beyond the settlement of the conversion obligation. Because time value make-whole provisions are not clearly and closely related to the debt host and would meet the definition of a derivative if considered freestanding, they are evaluated under the indexation guidance to determine whether they would be afforded the scope exception pursuant to ASC 815-10-15-74(a). This evaluation is generally performed in conjunction with the analysis of the embedded conversion feature. Company has measured its derivative liability at fair value and recognized the derivative value as a current liability and recorded the derivative value on its balance sheet. Changes in the fair value are recorded as a gain or loss in the accompanying statement of operations. The valuation of the Notes was done by using the Binomial Model, a well-accepted option-pricing model, and based on the Notes’ terms and other parameters the Company identified as relevant for the valuation of the Notes’ Fair Value. The Binomial Model used the forecast of the Company share price during the Note’s contractual term. As of September 30, 2021 and December 31, 2020, the Company’s liabilities that are measured at fair value are as follows: September 30, December 31, Level 3 Total Level 3 Total US$ US$ US$ US$ Fair value of derivative liability - - 431 431 Change in value of the derivative liability during 2021 is as follows: US$ Derivative liability fair value at December 31, 2020 431 Gain on derivative liability (431 ) Derivative liability fair value at September 30, 2021 - The following table presents the assumptions that were used for the model as of September 30, 2021: September 30, December 31, Convertible Option Fair Value of approximately $ - $ 431,000 Annual Risk-free Rate - .09 % Volatility - 163.57 % Expected Term (years) - .33 Convertible Notes Face Value $ - $ 3,246,700 Expected annual yield on Regular Notes - 28.77 % Price of the Underlying Stock $ - $ 0.90 During the three and nine months ended September 30, 2021, the Company recorded unrealized gains of approximately $ nil During the three and nine months ended September 30, 2020, the Company recorded unrealized gains (losses) of approximately $49,000, net, and ($2,000), net, respectively, within the Statements of Operations on derivative liability.

Right of Use Lease Assets and L

Right of Use Lease Assets and Lease Obligations	9 Months Ended
	Sep. 30, 2021
Right of Use Lease Assets and Leases Obligations [Abstract]
Right of use lease assets and lease obligations	Note 7 - Right of use lease assets and lease obligations The Company is a lessee in several non-cancellable operating leases, primarily for transportation and office spaces. The table below presents the operating lease assets and liabilities recognized on the balance sheets as of September 30, 2021 and December 31, 2020: September 30, December 31, US$ US$ Operating lease assets $ 390 $ 438 Operating lease liabilities: Current operating lease liabilities $ 228 $ 191 Non-current operating lease liabilities $ 200 $ 307 Total operating lease liabilities $ 428 $ 498 The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of September 30, 2021 are: September 30, Weighted average remaining lease term (years) 2.0 Weighted average discount rate 5.9 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed consolidated balance sheets as of September 30, 2021: US$ October 1, 2021 through December 31, 2021 72 2022 211 2023 156 2024 13 Thereafter - Total undiscounted future minimum lease payments 452 Less: portion representing imputed interest (24 ) Total undiscounted future minimum lease payments 428 Operating lease costs were $68,000 and $196,000 for the three and nine months ended September 30, 2021, respectively. Operating lease costs were $61,000 and $183,000 for the three and nine months ended September 30, 2020, respectively. Operating lease costs are included within general and administrative expenses on the statements of income. Cash paid for amounts included in the measurement of operating lease liabilities was $72,000 and $215,000 for the three and nine months ended September 30, 2021, respectively. Cash paid for amounts included in the measurement of operating lease liabilities were $69,000 and $203,000 for the three and nine months ended September 30, 2020. These amounts are included in operating activities in the statements of cash flows. Right-of-use assets obtained in exchange for new operating lease liabilities were $ nil nil nil

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies A. Securities and Exchange Commission (“SEC”) Investigation As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation. Since that date, we have fully cooperated with the SEC on an on-going basis in connection with its investigation. Investigations of this nature are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, an SEC investigation could have an adverse impact on us because of legal costs, diversion of management resources, and other factors. The investigation could also result in reputational harm to Zion and may have a material adverse effect on Zion’s current and future business and exploratory activities and its ability to raise capital to continue our oil and gas exploratory activities. B. Litigation On October 29, 2018, Zion received a shareholder request to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law for the purpose of investigating potential corporate mismanagement and alleged breaches of fiduciary duty in connection with public statements made by the Company from March 12, 2018 to May 30, 2018. The Company responded to this request. On August 9, 2019, Zion received two (2) additional shareholder requests from the same law firm to inspect books and records pursuant to section 220 of the Delaware General Corporation Law for the purpose of investigating potential corporate mismanagement and alleged breaches of fiduciary duty in connection with public statements made by the Company from February 1, 2018 to present. Following discussion with counsel to the shareholder, the Company’s counsel produced materials responsive to the shareholders’ request in January 2020. On February 12, 2020, by letter to Zion’s Board of Directors, one of the shareholders making the August 9, 2019 request demanded that the Board investigate, address, remedy, and commence proceedings against certain of the Company’s current and former officers and directors for alleged breaches of fiduciary duties, violations of section 10(b) and 20(a) of the Exchange Act, waste of corporate assets, unjust enrichment, and violations of all other applicable laws. The shareholder alleges wrongdoing in connection with public statements made by the Company from February 1, 2018 regarding the Company’s oil and gas exploration activities, the Company’s accounting and disclosure of expenses, and the Board’s oversight of operations. The Board hired independent counsel to investigate the claims made against certain of the Company’s current and former officers and directors. That investigation concluded and based on the findings and recommendations of independent counsel, the Board decided not to pursue claims against any current or former officer or director. On July 14, 2020, Zion received a request from the same shareholder making the February 12, 2020 demand to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law for the purpose of evaluating the Board’s decision to reject the litigation demand. The Company responded to this request in August 2020. The Company has not received any further communication from the shareholder following the August 2020 response. From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. The Company is not subject to any litigation at the present time. C. Recent Market Conditions – Coronavirus Pandemic During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic has significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments react to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. As of the date of this report, many of our employees are working from home. However, while there are various uncertainties to navigate, the Company’s business activities are continuing. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. We cannot predict whether, when or the manner in which the conditions surrounding COVID-19 will change including the timing of lifting any restrictions or work from home arrangements. The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others. D. Environmental and Onshore Licensing Regulatory Matters The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings. On April 8, 2019 the Energy Ministry issued new procedural guidelines regarding a uniform reporting manner by which the rights holder in a license must submit a quarterly report regarding a summary of license history, the nature, scope, location and results of the exploration work, specification of the amounts expended for the exploration work, and the results and interpretation of the exploration work and basic data on which these results and interpretation are based. On July 18, 2019, the Energy Ministry issued a guidance document entitled “Instructions for Submitting Guarantees with respect to Oil Rights granted pursuant to the Petroleum Law” which states that onshore license applicants are required to deposit a base bank guarantee of $500,000. Furthermore, prior to drilling, an onshore license holder is required to deposit an additional bank guarantee in the amount as determined by the Petroleum Commissioner in accordance with the characteristics of the drilling and the drilling plan but no less than $250,000. The guarantee, as determined by the Commissioner, shall be deposited with the Commissioner Office for each well separately drilled. The Petroleum Commissioner has discretion to raise or lower those amounts or may also forfeit a Company’s existing guarantee and/or cancel a petroleum right under certain circumstances. In addition, new and extended insurance policy guidelines were added. The Petroleum Commissioner may also view non-compliance with the new insurance provisions as breaching the work plan and the rights granted and act accordingly. The Company believes that these new regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these new regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells. As of September 30, 2021, and December 31, 2020, the Company accrued $0 for license regulatory matters. E. Bank Guarantees As of September 30, 2021, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately $1,179,000) and others (approximately $90,000) with respect to its drilling operation in an aggregate amount of approximately $1,269,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts and are reported on the Company’s balance sheets as fixed short-term bank deposits – restricted. F. Risks Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates. Foreign Currency Exchange Rate Risks. Interest Rate Risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 9 - Subsequent Events (i) Approximately $4,378,000 was collected through the Company’s DSPP program during the period October 1, through November 10, 2021.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Net Gain (Loss) per Share Data	A. Net Gain (Loss) per Share Data Basic and diluted net (loss) gain per share of common stock, par value $0.01 per share (“Common Stock”), is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share, as the inclusion of 21,810,891 and 17,471,772 and 10,219,066 and 10,404,146 Common Stock equivalents in the three- and nine-month period ended September 30, 2021 and 2020 respectively, would be anti-dilutive.
Use of Estimates	B. Use of Estimates The preparation of the accompanying consolidated condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.
Oil and Gas Properties and Impairment	C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the three and nine months ended September 30, 2021, and 2020, respectively, the Company did not record any post-impairment charges. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $39,439,000 and $15,526,000 as of September 30, 2021 and December 31, 2020, respectively.
Fair Value Measurements	D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At September 30, 2021, and December 31, 2020, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. Derivative instruments are carried at fair value, generally estimated using the Binomial Model.
Derivative Liabilities	E. Derivative Liabilities In accordance with ASC 815-40-25 and ASC 815-10-15 Derivatives and Hedging and ASC 480-10-25 Liabilities-Distinguishing Liabilities from Equity, the embedded derivatives associated with the Convertible Bonds are accounted for as a liability during the term of the related Convertible Bonds (see Note 5).
Stock-Based Compensation	F. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
Warrants	G. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity
Related parties	H. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report, with the exception of recurring monthly consulting fees paid to certain management personnel.
Recently Adopted Accounting Pronouncements	I. Recently Adopted Accounting Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its consolidated financial statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its unaudited consolidated condensed financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
Depreciation and Accounting for Drilling Rig and Inventory	J. Depreciation and Accounting for Drilling Rig and Inventory On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. We remitted to the Seller $250,000 on February 6, 2020 as earnest money towards the purchase price. The Closing anticipated by the Agreement took place on March 12, 2020 by the Seller’s execution and delivery of a Bill of Sale to us. On March 13, 2020, the Seller retained the earnest money deposit, and the Company remitted $4,350,000 to the seller towards the purchase price and $1,000,000 (the “Holdback Amount”) was deposited in escrow with American Stock Transfer and Trust Company LLC, as escrow agent, through November 30, 2020, or as extended by mutual agreement of the parties, pending a determination, if any, by us of any operating deficiency in the drilling rig. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021. Since the rig was purchased and closed during March 2020, this purchase was recorded on Zion’s books as a long-term fixed asset as a component of Property and Equipment. The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion has been depreciating the rig on a straight-line basis since it was placed in service. The $540,000 in spare parts was the original cost to CED. These items were received and counted by Zion upon receipt. All records and files are maintained by Zion. Zion plans to obtain a physical count of the equipment items at the end of each quarter, or as close to such date as practical, in accordance with our normal procedures. Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account and our straight-line amortization will be adjusted accordingly. See the table below for a reconciliation of the rig-related activity during the nine months ended September 30, 2021: I-35 Drilling Rig & Associated Equipment: I-35 Drilling Rig Spare Other Drilling Total US$ US$ US$ US$ December 31, 2020 6,494 698 376 7,568 Asset Additions - 89 26 115 Asset Depreciation (475 ) - (50) (525 ) Asset Disposals for Self-Consumption - (210 ) - (210 ) September 30, 2021 6,019 577 352 6,948

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of the costs of each certification will be added to the drilling rig account and our straight-line amortization	I-35 Drilling Rig Spare Other Drilling Total US$ US$ US$ US$ December 31, 2020 6,494 698 376 7,568 Asset Additions - 89 26 115 Asset Depreciation (475 ) - (50) (525 ) Asset Disposals for Self-Consumption - (210 ) - (210 ) September 30, 2021 6,019 577 352 6,948

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Stockholders’ Equity (Tables) [Line Items]
Schedule of stock option transactions	Number of Weighted Average US$ Outstanding, December 31, 2020 3,797,750 1.14 Changes during 2021 to: Granted to employees, officers, directors and others 7,023,000 0.49 Expired/Cancelled/Forfeited (183,000 ) 1.52 Exercised (372,000 ) 0.04 Outstanding, September 30, 2021 10,265,750 0.73 Exercisable, September 30, 2021 10,265,750 0.73
Schedule of stock options outstanding	Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number outstanding Weighted Weighted Range of Number Weighted average Weighted US$ US$ US$ US$ — — — — 0.01 10,000 2.12 0.01 — — — — 0.01 5,000 2.70 0.01 — — — — 0.01 20,000 4.67 0.01 — — — — 0.01 130,000 5.25 0.01 — — — — 0.01 50,000 5.26 0.01 — — — — 0.01 60,000 5.54 0.01 — — — — 0.01 200,000 5.63 0.01 — — — — 0.01 40,000 6.00 0.01 — — — — 0.01 87,500 6.25 0.01 — — — — 0.01 25,000 6.26 0.01 — — — — 0.01 30,000 6.41 0.01 — — — — 0.01 4,000 6.51 0.01 — — — — 0.01 25,000 7.26 0.01 — — — — 0.01 105,000 7.96 0.01 — — — — 0.01 220,000 8.13 0.01 — — — — 0.01 35,000 8.26 0.01 — — — — 0.01 75,000 9.26 0.01 — — — — 0.01 200,000 9.63 0.01 — — — — 0.01 355,000 9.79 0.01 — — — — 0.01 10,000 9.92 0.01 — — — — 0.16 340,000 4.19 0.16 — — — — 0.16 75,000 8.19 0.16 — — — — 0.18 25,000 4.17 0.18 — — — — 0.25 50,000 9.92 0.25 — — — — 0.25 363,000 9.92 0.25 — — — — 0.28 25,000 3.92 0.28 — — — — 0.28 25,000 7.92 0.28 — — — — 0.29 25,000 5.70 0.29 — — — — 0.39 1,515,000 9.77 0.39 — — — — 0.39 10,000 9.95 0.39 — — — — 0.59 1,400,000 5.63 0.59 — — — — 0.59 1,800,000 9.63 0.59 — — — — 0.92 350,000 5.26 0.92 — — — — 0.92 600,000 9.26 0.92 — — — — 1.33 25,000 1.57 1.33 — — — — 1.38 105,307 3.26 1.38 — — — — 1.55 200,000 0.68 1.55 — — — — 1.67 405,943 3.01 1.67 — — — — 1.70 218,500 1.22 1.70 — — — — 1.75 250,000 1.76 1.75 — — — — 1.78 25,000 2.93 1.78 — — — — 2.31 250,000 2.25 2.31 2.61 471,500 0.18 2.61 — — — — 4.15 25,000 2.76 4.15 0.01-4.15 10,265,750 0.73
Schedule of compensation cost of warrant and option issuances	For the three months ended September 30, 2021 2020 US$ thousands US$ thousands 727 3 For the nine months ended September 30, 2021 2020 US$ thousands US$ thousands 3,217 59 For the three months ended September 30, 2021 2020 US$ thousands US$ thousands 3 — For the nine months ended September 30, 2021 2020 US$ thousands US$ thousands 102 — For the three months ended September 30, 2021 2020 US$ thousands US$ thousands — — For the nine months ended September 30, 2021 2020 US$ thousands US$ thousands — —
Schedule of warrants description	Warrants Exercise Warrant Outstanding Balance, 12/31/2020 Warrants Warrants Exercised Warrants Expired Outstanding Balance, 09/30/2021 ZNWAA $ 2.00 01/31/2023 1,498,804 - - - 1,498,804 ZNWAD $ 1.00 05/02/2023 243,853 - - - 243,853 ZNWAE $ 1.00 05/01/2023 2,144,099 - - - 2,144,099 ZNWAF $ 1.00 08/14/2023 359,435 - - - 359,435 ZNWAG $ 1.00 01/08/2023 240,068 - - - 240,068 ZNWAH $ 5.00 04/19/2023 372,400 - - - 372,400 ZNWAI $ 3.00 06/29/2023 640,730 - - - 640,730 ZNWAJ $ 1.00 10/29/2023 545,900 - - - 545,900 ZNWAK $ 0.01 02/25/2023 437,875 - (6,220 ) - 431,655 ZNWAL $ 2.00 08/26/2023 517,875 - - - 517,875 ZNWAM $ 1.00 07/15/2022 - 4,376,000 - - 4,376,000 ZNWAN $ 1.00 07/15/2022 - 267,785 (100 ) - 267,685 ZNWAO $ 0.25 06/12/2023 - 190,480 (15,200 ) - 175,280 ZNWAP $ 0.25 06/02/2022 - 1,639,916 (1,200,000 ) - 439,916 ZNWAR $ 0.25 06/23/2022 - 1,020,000 - - 1,020,000 Outstanding warrants 7,001,039 7,494,181 (1,221,520 ) - 13,273,700
Employees [Member]
Stockholders’ Equity (Tables) [Line Items]
Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model	For the nine months ended 2021 2020 Weighted-average fair value of underlying stock at grant date $ 0.55 $ 0.50 Dividend yields — — Expected volatility 121%-143 % 90%-103 % Risk-free interest rates 0.16%-0.85 % 0.26%-1.61 % Expected lives (in years) 3.00-5.00 5.00 Weighted-average grant date fair value $ 0.47 $ 0.49
Non Employees [Member]
Stockholders’ Equity (Tables) [Line Items]
Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model	For the nine months ended 2021 2020 Weighted-average fair value of underlying stock at grant date $ 0.58 $ — Dividend yields — — Expected volatility 100%-113 % — Risk-free interest rates 1.07%-1.42 % — Expected lives (in years) 6.00-10.00 — Weighted-average grant date fair value $ 0.49 $ —
Investors [Member]
Stockholders’ Equity (Tables) [Line Items]
Schedule of warrants description	Period of Grant US$ Expiration Date ZNWAA Warrants B,C March 2013 – December 2014 2.00 January 31, 2023 ZNWAD Warrants A,B,C January 2015 – March 2016 1.00 May 02, 2023 ZNWAE Warrants B,C November 2016 – March 2017 1.00 May 01, 2023 ZNWAF Warrants A,B,C May 2017 – July 2017 1.00 August 14, 2023 ZNWAG Warrants C October 2017 – December 2017 1.00 January 08, 2023 ZNWAH Warrants A,B,C February 2018 5.00 April 2, 2023 ZNWAI Warrants A,B,C April 2018 – May 2018 3.00 June 29, 2023 ZNWAJ Warrants B,C August 2018 – September 2018 1.00 October 29, 2023 ZNWAK Warrants B,C December 2018 – January 2019 0.01 February 25, 2023 ZNWAL Warrants C July 2019 – August 2019 2.00 August 26, 2023 ZNWAM Warrants January 2021 – March 2021 1.00 July 15, 2022 ZNWAN Warrants May - June 2021 1.00 July 15, 2022 ZNWAO Warrants June 2021 0.25 June 12, 2023 ZNWAP Warrants June 2021 0.25 June 02, 2022 ZNWAQ Warrants June 2021 0.25 July 6, 2022 ZNWAR Warrants June 2021 0.25 June 22, 2022

Unproved Oil and Gas Properti_2

Unproved Oil and Gas Properties, Full Cost Method (Tables)	9 Months Ended
	Sep. 30, 2021
Oil and Gas Property [Abstract]
Schedule of unproved oil and gas properties, full cost method	September 30, December 31, US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 25,551 4,232 Capitalized salary costs 2,122 1,967 Capitalized interest costs 1,418 1,314 Legal and seismic costs, license fees and other preparation costs 10,309 7,974 Other costs 39 39 39,439 15,526
Schedule of changes in unproved oil and gas properties	For the three months ended For the nine months ended 2021 2020 2021 2020 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 6,727 79 21,319 163 Capitalized salary costs 38 56 155 153 Capitalized interest costs - 51 104 110 Legal costs, license fees and other preparation costs 573 318 2,335 716 Other costs - 4 - 15 *7,338 *508 *23,913 *1,157 * Inclusive of non-cash amounts of approximately $316,000, and $154,000 during the three months ended September 30, 2021, and 2020, respectively * Inclusive of non-cash amounts of approximately $3,218,000, and $293,000 during the nine months ended September 30, 2021, and 2020, respectively

Senior Convertible Bonds (Table

Senior Convertible Bonds (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of senior convertible bonds	September 30, December 31, US$ US$ 10% Senior Convertible Bonds, on the day of issuance $ - $ 3,470 Unamortized Debt discount, net $ - $ (205 ) Bonds converted to shares $ - $ (223 ) Offering cost, net $ - $ (9 ) 10% senior Convertible bond - Liability $ - $ 3,033

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of the company’s liabilities that are measured at fair value	September 30, December 31, Level 3 Total Level 3 Total US$ US$ US$ US$ Fair value of derivative liability - - 431 431
Schedule of change in value of the derivative liability	US$ Derivative liability fair value at December 31, 2020 431 Gain on derivative liability (431 ) Derivative liability fair value at September 30, 2021 -
Schedule of assumption used for the model of derivatives liabilities	September 30, December 31, Convertible Option Fair Value of approximately $ - $ 431,000 Annual Risk-free Rate - .09 % Volatility - 163.57 % Expected Term (years) - .33 Convertible Notes Face Value $ - $ 3,246,700 Expected annual yield on Regular Notes - 28.77 % Price of the Underlying Stock $ - $ 0.90

Right of Use Lease Assets and_2

Right of Use Lease Assets and Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2021
Right of Use Lease Assets and Leases Obligations [Abstract]
Schedule of operating lease assets and liabilities	September 30, December 31, US$ US$ Operating lease assets $ 390 $ 438 Operating lease liabilities: Current operating lease liabilities $ 228 $ 191 Non-current operating lease liabilities $ 200 $ 307 Total operating lease liabilities $ 428 $ 498
Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	September 30, Weighted average remaining lease term (years) 2.0 Weighted average discount rate 5.9 %
Schedule of future minimum lease payments under non-cancellable operating leases	US$ October 1, 2021 through December 31, 2021 72 2022 211 2023 156 2024 13 Thereafter - Total undiscounted future minimum lease payments 452 Less: portion representing imputed interest (24 ) Total undiscounted future minimum lease payments 428

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Going Concern (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)m²	Dec. 31, 2018USD ($)	Dec. 31, 2020USD ($)
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Area of land depth, description	MJ#1 had natural fractures, permeability (the ability of fluid to move through the rock) and porosity (pore space in rock) that allowed the sustained flow of formation fluid in the shallower Jurassic and lower Cretaceous age formations between approximately 1,200 and 1,800 meters. While no hydrocarbons were encountered, Zion believes this fact is nonetheless significant because it provides important information about possible reservoir pressures and the ability of fluids to move within the formation and to the surface.
Impairment of oil and gas properties		$ 30,906,000
Net loss	$ 8,900,000
Accumulated deficit	$ (221,723,000)		$ (212,804,000)
Megiddo-Jezreel Petroleum License [Member]
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Area of land, approximate | m²	99,000
Area of land depth, description	The Megiddo-Jezreel License 401 was awarded on December 3, 2013 for a three-year primary term through December 2, 2016 with the possibility of additional one-year extensions up to a maximum of seven years.
AGS [Member]
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Area of land, approximate | m²	72
MJ-02 Drilling Plan [Member] | Megiddo-Jezreel Petroleum License [Member]
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Area of land depth, description	Zion plans to reach a total depth of approximately 5,600 meters (~18,368 feet).
Exploration Rights [Member] | Megiddo-Jezreel Petroleum License [Member]
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Area of land depth, description	The Megiddo Jezreel #1 (“MJ #1”) exploratory well was spud on June 5, 2017 and drilled to a total depth (“TD”) of 5,060 meters (approximately 16,600 feet). Thereafter, the Company successfully cased and cemented the well while awaiting the approval of the testing protocol. The Ministry of Energy approved the well testing protocol on April 29, 2018.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 13, 2020	Feb. 06, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Mar. 12, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock, par value (in Dollars per share)				$ 0.01		$ 0.01		$ 0.01
Common stock equivalents excluded from EPS as the inclusion would be anti-dilutive (in Shares)				21,810,891	17,471,772	10,219,066	10,404,146
Capitalized exploration costs						$ 39,439,000		$ 15,526,000
Remaining amount held in escrow deposit			$ 250,000
Purchase price		$ 4,350,000
Purchase price of drilling ring	$ 5,600,000
Consumable inventory included in the rig purchase	540,000
Spare parts inventory	$ 48,000
Useful life of drilling rig						10 years
Purchase and Sale Agreement [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Equipment and excess inventory									$ 5,600,000
Escrow deposit		$ 1,000,000
Spare parts inventory				$ 540,000		$ 540,000
Useful life of drilling rig						5 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of the costs of each certification will be added to the drilling rig account and our straight-line amortization $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Summary of Significant Accounting Policies (Details) - Schedule of the costs of each certification will be added to the drilling rig account and our straight-line amortization [Line Items]
Beginning Balance	$ 7,568
Asset Additions	115
Asset Depreciation	(525)
Asset Disposals for Self-Consumption	(210)
Ending Balance	6,948
I-35 Drilling Rig [Member]
Summary of Significant Accounting Policies (Details) - Schedule of the costs of each certification will be added to the drilling rig account and our straight-line amortization [Line Items]
Beginning Balance	6,494
Asset Additions
Asset Depreciation	(475)
Asset Disposals for Self-Consumption
Ending Balance	6,019
Rig Spare Parts [Member]
Summary of Significant Accounting Policies (Details) - Schedule of the costs of each certification will be added to the drilling rig account and our straight-line amortization [Line Items]
Beginning Balance	698
Asset Additions	89
Asset Depreciation
Asset Disposals for Self-Consumption	(210)
Ending Balance	577
Other Drilling Assets [Member]
Summary of Significant Accounting Policies (Details) - Schedule of the costs of each certification will be added to the drilling rig account and our straight-line amortization [Line Items]
Beginning Balance	376
Asset Additions	26
Asset Depreciation	(50)
Asset Disposals for Self-Consumption
Ending Balance	$ 352

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 08, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Stockholders’ Equity (Details) [Line Items]
Common stock, par value		$ 0.01		$ 0.01		$ 0.01
Exercise price per unit		1		$ 1
Warrants termination, description				The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advance notice to the warrant holders. An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017. Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.”  The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2023 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advance notice to the warrant holders. On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.” The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.”
Warrant terms, description				The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advance notice to the warrant holders.
Offering cost, description				The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this unit offering. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.” The warrants became exercisable on August 26, 2019 and continue to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit program consisting of Units (shares of stock and warrants) to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant has the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2022 at a per share exercise price of $1.00. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.” Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continue to be exercisable through June 2, 2022 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued on April 4, 2022 and be exercisable through July 6, 2022 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account will be credited with the number of shares of the Company’s Common Stock and Warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be exercisable on November 15, 2023 and continue to be exercisable through December 31, 2023 at a per share exercise price of $1.00. On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein. For the three and nine months ended September 30, 2021, approximately $4,369,000, and $18,157,000 were raised under the DSPP program, respectively. For the three and nine months ended September 30, 2020, approximately $13,015,000, and $25,517,000 were raised under the DSPP program, respectively. The company raised approximately $4,378,000 from the period October 1, 2021 through November 10, 2021, under the DSPP program.The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants described above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only.
Issuance costs				$ 115,000
Exercise price		$ 1		$ 1
Raised under program amount		$ 4,369,000	$ 13,015,000	$ 18,157,000	$ 25,517,000
Subsequent Event [Member]
Stockholders’ Equity (Details) [Line Items]
Raised under program amount	$ 4,378,000
Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Subscription rights offering, description				Each shareholder received.10 (one tenth) of a Subscription Right (i.e., one Subscription Right for each 10 shares owned) for each share of the Company’s Common Stock owned on the Record Date.
Amended and Restated Certificate of Incorporation [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, par value		$ 0.01		$ 0.01
One Board [Member]
Stockholders’ Equity (Details) [Line Items]
Fair value of stock options granted				$ 87,000
ZNWAF Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023.
Unit Option Program [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				The warrants became exercisable on June 29, 2018 and continued to be exercisable through June 29, 2020 at a per share exercise price of $3.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of June 29, 2019 to June 29, 2020.
Minimum [Member] | Amended and Restated Certificate of Incorporation [Member]
Stockholders’ Equity (Details) [Line Items]
Increase in shares authorized		400,000,000		400,000,000
Maximum [Member] | Amended and Restated Certificate of Incorporation [Member]
Stockholders’ Equity (Details) [Line Items]
Increase in shares authorized		800,000,000		800,000,000
ZNWAI Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023.
ZNWAE Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023.
Znwaf [Member] | Unit Option Program [Member]
Stockholders’ Equity (Details) [Line Items]
New unit program, description				This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit program terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.”
Znwaf [Member] | Unit Option Program [Member]
Stockholders’ Equity (Details) [Line Items]
Offering cost, description				The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01.
ZNWAJ Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021.
ZNWAJ Warrant [Member] | Unit Option Program [Member]
Stockholders’ Equity (Details) [Line Items]
Warrants termination, description				The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020.
ZNWAJ Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023.
Subscription Rights Offering [Member]
Stockholders’ Equity (Details) [Line Items]
Subscription rights offering, description				On April 2, 2018 the Company announced an offering (“2018 Subscription Rights Offering”) through American Stock Transfer & Trust Company, LLC (the “Subscription Agent”), at no cost to the shareholders, of non-transferable Subscription Rights (each “Right” and collectively, the “Rights”) to purchase its securities to persons who owned shares of our Common Stock on April 13, 2018 (“the Record Date”). Pursuant to the 2018 Subscription Rights Offering, each holder of shares of common stock on the Record Date received non-transferable Subscription Rights, with each Right comprised of one share of the Company Common Stock, par value $0.01 per share (the “Common Stock”) and one Common Stock Purchase Warrant to purchase an additional one share of Common Stock. Each Right could be exercised or subscribed at a per Right subscription price of $5.00. Each Warrant affords the investor the opportunity to purchase one share of the Company Common Stock at a warrant exercise price of $3.00. The warrant is referred to as “ZNWAI.”
ZNWAI Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On May 29, 2019, the Company extended the termination date of the ZNWAI Warrant by one (1) year from the expiration date of June 29, 2020 to June 29, 2021.
ZNWAI Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Expiration date, description				On September 15, 2020, the Company extended the termination date of the ZNWAI Warrant by two (2) years from the expiration date of June 29, 2021 to June 29, 2023.
2011 Equity Incentive Stock Option Plan [Member] | Six Senior Officers [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				600,000
Exercise price per unit		$ 0.915		$ 0.915
Stock option plan, expiration date				The options vested upon grant and are exercisable through January 4, 2031.
Fair value of stock options granted				$ 456,000
2011 Equity Incentive Stock Option Plan [Member] | One senior officer [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				75,000
Exercise price per unit		0.01		$ 0.01
Stock option plan, expiration date				The options vested upon grant and are exercisable through January 6, 2031
Fair value of stock options granted				$ 68,000
2011 Equity Incentive Stock Option Plan [Member] | Six Senior Officers One [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				1,800,000
Exercise price per unit		0.59		$ 0.59
Stock option plan, expiration date				The options vested upon grant and are exercisable through May 21, 2031.
Fair value of stock options granted				$ 885,000
2011 Equity Incentive Stock Option Plan [Member] | One Senior Officer One [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				200,000
Exercise price per unit		0.01		$ 0.01
Stock option plan, expiration date				The options vested upon grant and are exercisable through May 21, 2031.
Fair value of stock options granted				$ 117,000
2011 Equity Incentive Stock Option Plan [Member] | Five Senior Officers [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				110,000
Exercise price per unit		$ 0.01		$ 0.01
2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				3,038,000
Shares of common stock		38,000,000		38,000,000
Exercisable period				10 years
Deducting fees and expenses				$ 243,000
2021 Omnibus Incentive Stock Option Plan [Member] | Five Senior Officers [Member]
Stockholders’ Equity (Details) [Line Items]
Stock option plan, expiration date				The options vested upon grant and are exercisable through January 6, 2030.
Fair value of stock options granted				$ 57,000
2021 Omnibus Incentive Stock Option Plan [Member] | One Staff [Member]
Stockholders’ Equity (Details) [Line Items]
Stock option plan, expiration date				The options vested upon grant and are exercisable through September 1, 2031.
Fair value of stock options granted				$ 2,000
Exercise price per share		$ 0.01		$ 0.01
2021 Omnibus Incentive Stock Option Plan [Member] | Seven Board [Member]
Stockholders’ Equity (Details) [Line Items]
Stock option plan, expiration date				The options vested upon grant and are exercisable through July 13, 2031.
Exercise price per share		$ 0.39		$ 0.39
2021 Omnibus Incentive Stock Option Plan [Member] | One Board [Member]
Stockholders’ Equity (Details) [Line Items]
Option to purchase shares of common stock		413,000		413,000
Exercise price per share		$ 0.25		$ 0.25
2021 Omnibus Incentive Stock Option Plan [Member] | One Board One [Member]
Stockholders’ Equity (Details) [Line Items]
Stock option plan, expiration date				The options vested upon grant and are exercisable through June 15, 2031.
Fair value of stock options granted				$ 6,000
2021 Omnibus Incentive Stock Option Plan [Member] | Eleven Board [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				1,425,000
Stock option plan, expiration date				The options vested upon grant and are exercisable through July 09, 2031.
Fair value of stock options granted				$ 468,000
Exercise price per share		$ 0.39		$ 0.39
2021 Omnibus Incentive Stock Option Plan [Member] | Seven Staff [Members]
Stockholders’ Equity (Details) [Line Items]
Fair value of stock options granted				$ 33,000
Option to purchase shares of common stock		100,000		100,000
2021 Omnibus Incentive Stock Option Plan [Member] | Two Board Members and Six Staff [Member]
Stockholders’ Equity (Details) [Line Items]
Option to purchase shares of common stock		375,000		375,000
Exercise price per share		$ 0.01		$ 0.01
2021 Omnibus Incentive Stock Option Plan [Member] | Two Board [Member]
Stockholders’ Equity (Details) [Line Items]
Fair value of stock options granted				$ 140,000
Option to purchase shares of common stock		10,000		10,000
2021 Equity Omnibus Plan for Employee [Member] | One Staff [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				10,000
Exercise price per unit		$ 0.01		$ 0.01
Stock option plan, expiration date				The options vested upon grant and are exercisable through September 1, 2030.
Fair value of stock options granted				$ 2,000
2021 Equity Omnibus Plan for Employee [Member] | One Board [Member]
Stockholders’ Equity (Details) [Line Items]
Option to purchase shares of common stock		25,000		25,000
2021 Equity Omnibus Plan for Employee [Member] | One Board One [Member]
Stockholders’ Equity (Details) [Line Items]
Exercise price per share		$ 0.29		$ 0.29
2011 Non-Employee Directors Stock Option Plan [Member] | Seven Board [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				350,000
Exercise price per unit		0.915		$ 0.915
Stock option plan, expiration date				The options vested upon grant and are exercisable through January 4, 2027.
Fair value of stock options granted				$ 252,000
2011 Non-Employee Directors Stock Option Plan [Member] | One Board [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				50,000
Exercise price per unit		0.01		$ 0.01
Stock option plan, expiration date				The options vested upon grant and are exercisable through January 4, 2027
Fair value of stock options granted				$ 45,000
2011 Non-Employee Directors Stock Option Plan [Member] | Six Board [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				1,400,000
Exercise price per unit		0.59		$ 0.59
Stock option plan, expiration date				The options vested upon grant and are exercisable through May 21, 2027.
Fair value of stock options granted				$ 643,000
2011 Non-Employee Directors Stock Option Plan [Member] | One Board One [Member]
Stockholders’ Equity (Details) [Line Items]
Shares purchased under option plan				200,000
Exercise price per unit		0.01		$ 0.01
Stock option plan, expiration date				The options vested upon grant and are exercisable through May 21, 2027.
Fair value of stock options granted				$ 116,000
2011 Non-Employee Directors Stock Option Plan [Member] | Two Board Members and Six Employees [Member]
Stockholders’ Equity (Details) [Line Items]
Stock option plan, expiration date				The options vested upon grant and are exercisable through July 17, 2031.
Dividend Reinvestment And Stock Purchase Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, par value		$ 5		$ 5
Warrants termination, description				The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00.
Unit option, description				On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10.

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of stock option transactions - Employee Stock Option [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021
Stockholders’ Equity (Details) - Schedule of stock option transactions [Line Items]
Number of shares, Outstanding, Beginning	3,797,750
Weighted Average exercise price, Outstanding, Beginning	$ 1.14
Number of shares, Outstanding, Ending	10,265,750
Weighted Average exercise price, Outstanding, Ending	$ 0.73
Number of shares, Exercisable	10,265,750
Weighted Average exercise price, Exercisable	$ 0.73
Changes during 2021 to:
Number of shares, Granted to employees, officers, directors and others	7,023,000
Weighted Average exercise price, Granted to employees, officers, directors and others	$ 0.49
Number of shares, Expired/Cancelled/Forfeited	(183,000)
Weighted Average exercise price, Expired/Cancelled/Forfeited	$ 1.52
Number of shares, Exercised	(372,000)
Weighted Average exercise price, Exercised	$ 0.04

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of stock options outstanding	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares	10,265,750
Weighted Average Exercise price	$ 0.73
Minimum [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.01
Maximum [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	4.15
Ranges One [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges One [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	2 years 1 month 13 days
Weighted Average Exercise price	$ 0.01
Ranges Two [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Two [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	5,000
Weighted average remaining contractual life (years)	2 years 8 months 12 days
Weighted Average Exercise price	$ 0.01
Ranges Three [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Three [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	20,000
Weighted average remaining contractual life (years)	4 years 8 months 1 day
Weighted Average Exercise price	$ 0.01
Ranges Four [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Four [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	130,000
Weighted average remaining contractual life (years)	5 years 3 months
Weighted Average Exercise price	$ 0.01
Ranges Five [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Five [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	5 years 3 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Six [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Six [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	60,000
Weighted average remaining contractual life (years)	5 years 6 months 14 days
Weighted Average Exercise price	$ 0.01
Ranges Seven [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Seven [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	5 years 7 months 17 days
Weighted Average Exercise price	$ 0.01
Ranges Eight [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Eight [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	40,000
Weighted average remaining contractual life (years)	6 years
Weighted Average Exercise price	$ 0.01
Ranges Nine [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Nine [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	87,500
Weighted average remaining contractual life (years)	6 years 3 months
Weighted Average Exercise price	$ 0.01
Ranges Ten [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Ten [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	6 years 3 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Eleven [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Eleven [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	30,000
Weighted average remaining contractual life (years)	6 years 4 months 28 days
Weighted Average Exercise price	$ 0.01
Ranges Twelve [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twelve [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	4,000
Weighted average remaining contractual life (years)	6 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Thirteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	7 years 3 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Fifteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	105,000
Weighted average remaining contractual life (years)	7 years 11 months 15 days
Weighted Average Exercise price	$ 0.01
Ranges Fifteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	220,000
Weighted average remaining contractual life (years)	8 years 1 month 17 days
Weighted Average Exercise price	$ 0.01
Ranges Sixteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Sixteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	8 years 3 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Eighteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Eighteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	9 years 3 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Nineteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Nineteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	9 years 7 months 17 days
Weighted Average Exercise price	$ 0.01
Ranges Nineteen [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Nineteen [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	355,000
Weighted average remaining contractual life (years)	9 years 9 months 14 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	9 years 11 months 1 day
Weighted Average Exercise price	$ 0.01
Ranges Twenty One [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty One [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number outstanding (in Shares) | shares	340,000
Weighted average remaining contractual life (years)	4 years 2 months 8 days
Weighted Average Exercise price	$ 0.16
Ranges Twenty Two [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Two [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	8 years 2 months 8 days
Weighted Average Exercise price	$ 0.16
Ranges Twenty Two [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Two [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	4 years 2 months 1 day
Weighted Average Exercise price	$ 0.18
Ranges Twenty Four [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Four [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	9 years 11 months 1 day
Weighted Average Exercise price	$ 0.25
Ranges Twenty Five [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Five [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number outstanding (in Shares) | shares	363,000
Weighted average remaining contractual life (years)	9 years 11 months 1 day
Weighted Average Exercise price	$ 0.25
Ranges Twenty Four [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Four [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 years 11 months 1 day
Weighted Average Exercise price	$ 0.28
Ranges Twenty Seven [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Seven [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	7 years 11 months 1 day
Weighted Average Exercise price	$ 0.28
Ranges Twenty Five [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Five [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.29
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	5 years 8 months 12 days
Weighted Average Exercise price	$ 0.29
Ranges Twenty Nine [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Nine [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.39
Number outstanding (in Shares) | shares	1,515,000
Weighted average remaining contractual life (years)	9 years 9 months 7 days
Weighted Average Exercise price	$ 0.39
Ranges Thirty [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.39
Number outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	9 years 11 months 12 days
Weighted Average Exercise price	$ 0.39
Ranges Twenty Six [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Six [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number outstanding (in Shares) | shares	1,400,000
Weighted average remaining contractual life (years)	5 years 7 months 17 days
Weighted Average Exercise price	$ 0.59
Ranges Twenty Seven [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Seven [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number outstanding (in Shares) | shares	1,800,000
Weighted average remaining contractual life (years)	9 years 7 months 17 days
Weighted Average Exercise price	$ 0.59
Ranges Twenty Eight [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Eight [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number outstanding (in Shares) | shares	350,000
Weighted average remaining contractual life (years)	5 years 3 months 3 days
Weighted Average Exercise price	$ 0.92
Ranges Twenty Nine Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Nine Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number outstanding (in Shares) | shares	600,000
Weighted average remaining contractual life (years)	9 years 3 months 3 days
Weighted Average Exercise price	$ 0.92
Ranges Thirty [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.33
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 6 months 25 days
Weighted Average Exercise price	$ 1.33
Ranges Thirty One [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty One [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.38
Number outstanding (in Shares) | shares	105,307
Weighted average remaining contractual life (years)	3 years 3 months 3 days
Weighted Average Exercise price	$ 1.38
Ranges Thirty Two [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Two [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.55
Number outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	8 months 4 days
Weighted Average Exercise price	$ 1.55
Ranges Thirty Three [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Three [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.67
Number outstanding (in Shares) | shares	405,943
Weighted average remaining contractual life (years)	3 years 3 days
Weighted Average Exercise price	$ 1.67
Ranges Thirty Four [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Four [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.7
Number outstanding (in Shares) | shares	218,500
Weighted average remaining contractual life (years)	1 year 2 months 19 days
Weighted Average Exercise price	$ 1.7
Ranges Thirty Five [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Five [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.75
Number outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	1 year 9 months 3 days
Weighted Average Exercise price	$ 1.75
Ranges Thirty Six [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Six [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.78
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 11 months 4 days
Weighted Average Exercise price	$ 1.78
Ranges Thirty Seven [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Seven [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 2.31
Number outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	2 years 3 months
Weighted Average Exercise price	$ 2.31
Ranges Thirty Eight [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 2.61
Number outstanding (in Shares) | shares	471,500
Weighted average remaining contractual life (years)	2 months 4 days
Weighted Average Exercise price	$ 2.61
Ranges Thirty Nine [Member] | Non-vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Nine [Member] | Vested [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 4.15
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 9 months 3 days
Weighted Average Exercise price	$ 4.15

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model - Employees [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.55	$ 0.5
Dividend yields
Expected lives (in years)		5 years
Weighted-average grant date fair value (in Dollars per share)	$ 0.47	$ 0.49
Minimum [Member]
Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Expected volatility	121.00%	90.00%
Risk-free interest rates	0.16%	0.26%
Expected lives (in years)	3 years
Maximum [Member]
Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Expected volatility	143.00%	103.00%
Risk-free interest rates	0.85%	1.61%
Expected lives (in years)	5 years

Stockholders_ Equity (Details_4

Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model - Non-Employee [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.58
Dividend yields
Expected volatility
Risk-free interest rates
Expected lives (in years)
Weighted-average grant date fair value (in Dollars per share)	$ 0.49
Minimum [Member]
Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Expected volatility	100.00%
Risk-free interest rates	1.07%
Expected lives (in years)	6 years
Maximum [Member]
Stockholders’ Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Expected volatility	113.00%
Risk-free interest rates	1.42%
Expected lives (in years)	10 years

Stockholders_ Equity (Details_5

Stockholders’ Equity (Details) - Schedule of compensation cost of warrant and option issuances - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employees and Directors [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost of warrant and option issuances	$ 727	$ 3	$ 3,217	$ 59
Non-Employee [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost of warrant and option issuances	3		102
Unproved Oil & Gas properties [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost of warrant and option issuances

Stockholders_ Equity (Details_6

Stockholders’ Equity (Details) - Schedule of warrants description	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Outstanding Balance Beginning	7,001,039
Warrants Issued	7,494,181
Warrants Exercised	(1,221,520)
Warrants Expired
Outstanding Balance Ending	13,273,700
ZNWAA Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 2
Warrant Termination Date	Jan. 31, 2023
Outstanding Balance Beginning	1,498,804
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	1,498,804
ZNWAD Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	May 2, 2023
Outstanding Balance Beginning	243,853
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	243,853
ZNWAE Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	May 1, 2023
Outstanding Balance Beginning	2,144,099
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	2,144,099
ZNWAF Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Aug. 14, 2023
Outstanding Balance Beginning	359,435
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	359,435
ZNWAG Warrant [Member | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Jan. 8, 2023
Outstanding Balance Beginning	240,068
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	240,068
ZNWAH Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 5
Warrant Termination Date	Apr. 19, 2023
Outstanding Balance Beginning	372,400
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	372,400
ZNWAI Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 3
Warrant Termination Date	Jun. 29, 2023
Outstanding Balance Beginning	640,730
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	640,730
ZNWAJ Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Oct. 29, 2023
Outstanding Balance Beginning	545,900
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	545,900
ZNWAK Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.01
Warrant Termination Date	Feb. 25, 2023
Outstanding Balance Beginning	437,875
Warrants Issued
Warrants Exercised	(6,220)
Warrants Expired
Outstanding Balance Ending	431,655
ZNWAL Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 2
Warrant Termination Date	Aug. 26, 2023
Outstanding Balance Beginning	517,875
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	517,875
ZNWAM Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Jul. 15, 2022
Outstanding Balance Beginning
Warrants Issued	4,376,000
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	4,376,000
ZNWAN Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Jul. 15, 2022
Outstanding Balance Beginning
Warrants Issued	267,785
Warrants Exercised	(100)
Warrants Expired
Outstanding Balance Ending	267,685
ZNWAO Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jun. 12, 2023
Outstanding Balance Beginning
Warrants Issued	190,480
Warrants Exercised	(15,200)
Warrants Expired
Outstanding Balance Ending	175,280
ZNWAP Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jun. 2, 2022
Outstanding Balance Beginning
Warrants Issued	1,639,916
Warrants Exercised	(1,200,000)
Warrants Expired
Outstanding Balance Ending	439,916
ZNWAR Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jun. 23, 2022
Outstanding Balance Beginning
Warrants Issued	1,020,000
Warrants Exercised
Warrants Expired
Outstanding Balance Ending	1,020,000

Stockholders_ Equity (Details_7

Stockholders’ Equity (Details) - Schedule of warrants description - Investor [Member]	9 Months Ended
	Sep. 30, 2021$ / shares	[3]
ZNWAA Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAA Warrants	[1],[2]
Period of Grant	March 2013 – December 2014	[1],[2]
Exercise Price	$ 2	[1],[2]
Expiration Date	January 31, 2023	[1],[2]
ZNWAD Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAD Warrants	[1],[2],[4]
Period of Grant	January 2015 – March 2016	[1],[2],[4]
Exercise Price	$ 1	[1],[2],[4]
Expiration Date	May 02, 2023	[1],[2],[4]
ZNWAE Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAE Warrants	[1],[2]
Period of Grant	November 2016 – March 2017	[1],[2]
Exercise Price	$ 1	[1],[2]
Expiration Date	May 01, 2023	[1],[2]
ZNWAF Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAF Warrants	[1],[2],[4]
Period of Grant	May 2017 – July 2017	[1],[2],[4]
Exercise Price	$ 1	[1],[2],[4]
Expiration Date	August 14, 2023	[1],[2],[4]
ZNWAG Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAG Warrants	[2]
Period of Grant	October 2017 – December 2017	[2]
Exercise Price	$ 1	[2]
Expiration Date	January 08, 2023	[2]
ZNWAH Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAH Warrants	[1],[2],[4]
Period of Grant	February 2018	[1],[2],[4]
Exercise Price	$ 5	[1],[2],[4]
Expiration Date	April 2, 2023	[1],[2],[4]
ZNWAI Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAI Warrants	[1],[2],[4]
Period of Grant	April 2018 – May 2018	[1],[2],[4]
Exercise Price	$ 3	[1],[2],[4]
Expiration Date	June 29, 2023	[1],[2],[4]
ZNWAJ Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAJ Warrants	[1],[2]
Period of Grant	August 2018 – September 2018	[1],[2]
Exercise Price	$ 1	[1],[2]
Expiration Date	October 29, 2023	[1],[2]
ZNWAK Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAK Warrants	[1],[2]
Period of Grant	December 2018 – January 2019	[1],[2]
Exercise Price	$ 0.01	[1],[2]
Expiration Date	February 25, 2023	[1],[2]
ZNWAL Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAL Warrants	[2]
Period of Grant	July 2019 – August 2019	[2]
Exercise Price	$ 2	[2]
Expiration Date	August 26, 2023	[2]
ZNWAM Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAM Warrants
Period of Grant	January 2021 – March 2021
Exercise Price	$ 1
Expiration Date	July 15, 2022
ZNWAN Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAN Warrants
Period of Grant	May - June 2021
Exercise Price	$ 1
Expiration Date	July 15, 2022
ZNWAO Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAO Warrants
Period of Grant	June 2021
Exercise Price	$ 0.25
Expiration Date	June 12, 2023
ZNWAP Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAP Warrants
Period of Grant	June 2021
Exercise Price	$ 0.25
Expiration Date	June 02, 2022
ZNWAQ Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAQ Warrants
Period of Grant	June 2021
Exercise Price	$ 0.25
Expiration Date	July 6, 2022
ZNWAR Warrants [Member]
Class of Warrant or Right [Line Items]
Name	ZNWAR Warrants
Period of Grant	June 2021
Exercise Price	$ 0.25
Expiration Date	June 22, 2022
[1]	On May 29, 2019, the Company extended the termination date of the Warrants by one (1) year.
[2]	On September 15, 2020, the Company extended the termination date of the Warrants by two (2) years.
[3]	Zion’s ZNWAB Warrants expired on May 2, 2017, and the ZNWAC Warrants expired on May 2, 2018
[4]	On December 4, 2018, the Company extended the termination date of the Warrants by one (1) year.

Unproved Oil and Gas Properti_3

Unproved Oil and Gas Properties, Full Cost Method (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Oil and Gas Property [Abstract]
Inclusive of non-cash amounts	$ 316,000	$ 154,000	$ 3,218,000	$ 293,000

Unproved Oil and Gas Properti_4

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of unproved oil and gas properties, full cost method - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Excluded from amortization base:
Drilling costs, and other operational related costs	$ 25,551	$ 4,232
Capitalized salary costs	2,122	1,967
Capitalized interest costs	1,418	1,314
Legal and seismic costs, license fees and other preparation costs	10,309	7,974
Other costs	39	39
Total unproved oil and gas properties, full cost method	$ 39,439	$ 15,526

Unproved Oil and Gas Properti_5

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of changes in unproved oil and gas properties - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Excluded from amortization base:
Drilling costs, and other operational related costs		$ 6,727	$ 79	$ 21,319	$ 163
Capitalized salary costs		38	56	155	153
Capitalized interest costs			51	104	110
Legal costs, license fees and other preparation costs		573	318	2,335	716
Other costs			4		15
Changes in unproved oil and gas properties, full cost method	[1],[2]	$ 7,338	$ 508	$ 23,913	$ 1,157
[1]	Inclusive of non-cash amounts of approximately $3,218,000, and $293,000 during the nine months ended September 30, 2021, and 2020, respectively
[2]	Inclusive of non-cash amounts of approximately $316,000, and $154,000 during the three months ended September 30, 2021, and 2020, respectively

Senior Convertible Bonds (Detai

Senior Convertible Bonds (Details)	May 02, 2016USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)	Oct. 21, 2015$ / shares
Senior Convertible Bonds (Details) [Line Items]
Principal amount						$ 3,246,700
Convertible bonds						$ 3,470,000
Amortization expense			$ 7,000		$ 20,000
Debt discount amortization net			97,000		314,000
Financing costs associated notes converted to shares			$ 0		$ 3,000
Settle of bond, description				the ability of bondholders to convert the bonds ended so the 30-day average share price could be computed. On May 2, 2021, Zion’s bonds expired. Zion chose to pay the principal in kind with our stock. On May 2, 2021, a total of 32,139 $100 face value bonds were outstanding. The 30-day moving average price used to settle the bonds was $.606. Zion settled the principal on the bonds by issuing approximately 5,300,000 shares of our common stock. The annual 10% coupon payment was paid in shares using the same 30-day average price. Zion issued approximately 530,000 shares for the remaining bond holders’ interest payment.
Convertible bond price, description				Through the three and nine months ended September 30, 2020, 0 and 28 convertible bonds of $100 each, respectively, have been converted at a conversion rate of approximately $2.27 per share.
Common stock issued (in Shares) | shares			0	14,600	1,232
Financial expenses		$ 1,000		$ 24,000	$ 3,000
Capitalized interest			51,000	104,000	110,000
Interest expense			$ 31,000		$ 132,000
Convertible Debt [Member]
Senior Convertible Bonds (Details) [Line Items]
Amortization expense				9,000
Debt discount amortization net				205,000
Financing costs associated notes converted to shares				$ 24,000
Debt instrument payment description				The Notes were senior unsecured obligations of the Company and had an interest rate of 10% per year, payable annually in arrears on May 2 of each year, commencing May 2, 2017.
May 2, 2021 [Member] | Convertible Debt [Member]
Senior Convertible Bonds (Details) [Line Items]
Senior unsecured notes interest rate							10.00%
Debt conversion, description				Under this rights offering, we distributed at no cost, 360,000 non-transferable subscription rights to subscribe for, on a per right basis, two 10% Convertible Senior Bonds par $100 due May 2, 2021 (the “Notes”), to shareholders of the Company’s Common Stock on October 15, 2015, the record date for the offering. Each whole subscription right entitled the participant to purchase two convertible bonds at a purchase price of $100 per bond.
Convertible bonds purchase price (in Dollars per share) | $ / shares							$ 100
Principal amount	$ 3,470,000	3,470,000		$ 3,470,000
Net proceeds from sale of the notes	3,334,000
Expenses from rights offering	$ 136,000
Convertible bonds		1,844,000		1,844,000
Debt discount on derivative liability		$ 1,626,000		$ 1,626,000
Debt Issue [Member]
Senior Convertible Bonds (Details) [Line Items]
Debt instrument payment description				the Company paid its annual 10% interest to its bondholders of record on April 20, 2021. The interest was paid-in-kind (“PIK”) in the form of Common Stock. An average of the Company stock price of $.606 was determined based on the 30 trading days prior to the record date of April 20, 2021. This figure was used to divide into 10% of the par value of the bonds held by the holders. The Company issued approximately 530,000 shares to the accounts of its bondholders. Additionally, on May 3, 2021, the Company issued approximately 5,300,000 shares to the accounts of its bondholders in payment of the principal amount of the convertible bonds. As of the date of this report, the Company fully paid its annual interest over the course of five years, as well as the principal amount of the bonds, and its obligation is completed.
Debt Issue [Member] | Convertible Debt [Member]
Senior Convertible Bonds (Details) [Line Items]
Debt instrument payment description				The number of shares for the payment of principal, in lieu of the cash amount, shall be based upon the average of the closing price of the Company’s Common Stock as reported by Bloomberg L.P. for the 30 trading days preceding the principal repayment date; such record date has been designated as the trading day immediately prior to the 30-day period preceding the maturity date of May 2, 2021.
Convertible Bonds [Member]
Senior Convertible Bonds (Details) [Line Items]
Convertible bonds purchase price (in Dollars per share) | $ / shares		$ 2.27	$ 2.27	$ 2.27	$ 2.27
Convertible bond price, description				Through the three and nine months ended September 30, 2021, nil and 332 convertible bonds of $100 each, respectively, have been converted at a conversion rate of approximately $2.27 per share.
Number of convertible bonds			0	332	28

Senior Convertible Bonds (Det_2

Senior Convertible Bonds (Details) - Schedule of senior convertible bonds - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Schedule of senior convertible bonds [Abstract]
10% Senior Convertible Bonds, on the day of issuance		$ 3,470
Unamortized Debt discount, net		(205)
Bonds converted to shares		(223)
Offering cost, net		(9)
10% senior Convertible bond - Liability		$ 3,033

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Unrealized gains (losses) on derivative liability		$ 49,000	$ 431,000	$ (2,000)

Derivative Liability (Details)

Derivative Liability (Details) - Schedule of the company’s liabilities that are measured at fair value - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Derivative Liability (Details) - Schedule of the company’s liabilities that are measured at fair value [Line Items]
Fair value of derivative liability		$ 431
Fair Value, Inputs, Level 3 [Member]
Derivative Liability (Details) - Schedule of the company’s liabilities that are measured at fair value [Line Items]
Fair value of derivative liability		$ 431

Derivative Liability (Details_2

Derivative Liability (Details) - Schedule of change in value of the derivative liability $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Schedule of change in value of the derivative liability [Abstract]
Derivative liability fair value at December 31, 2020	$ 431
Gain on derivative liability	(431)
Derivative liability fair value at September 30, 2021

Derivative Liability (Details_3

Derivative Liability (Details) - Schedule of assumption used for the model of derivatives liabilities - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Schedule of assumption used for the model of derivatives liabilities [Abstract]
Convertible Option Fair Value of approximately (in Dollars)		$ 431,000
Annual Risk-free Rate		0.09%
Volatility		163.57%
Expected Term (years)		33 years
Convertible Notes Face Value (in Dollars)		$ 3,246,700
Expected annual yield on Regular Notes		28.77%
Price of the Underlying Stock (in Dollars per share)		$ 0.9

Right of Use Lease Assets and_3

Right of Use Lease Assets and Lease Obligations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Right of Use Lease Assets and Leases Obligations [Abstract]
Operating lease costs	$ 68,000	$ 61,000	$ 196,000	$ 183,000
Operating lease liabilities	72,000	69,000	215,000	203,000
Right-of-use assets obtained in exchange for new operating lease liabilities			$ 128,000

Right of Use Lease Assets and_4

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of operating lease assets and liabilities - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Schedule of operating lease assets and liabilities [Abstract]
Operating lease assets	$ 390	$ 438
Operating lease liabilities:
Current operating lease liabilities	228	191
Non-current operating lease liabilities	200	307
Total operating lease liabilities	$ 428	$ 498

Right of Use Lease Assets and_5

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	Sep. 30, 2021
Schedule of weighted average remaining lease term and weighted average discount rate for operating leases [Abstract]
Weighted average remaining lease term (years)	2 years
Weighted average discount rate	5.90%

Right of Use Lease Assets and_6

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of future minimum lease payments under non-cancellable operating leases $ in Thousands	Sep. 30, 2021USD ($)
Schedule of future minimum lease payments under non-cancellable operating leases [Abstract]
October 1, 2021 through December 31, 2021	$ 72
2022	211
2023	156
2024	13
Thereafter
Total undiscounted future minimum lease payments	452
Less: portion representing imputed interest	(24)
Total undiscounted future minimum lease payments	$ 428

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Jul. 18, 2019	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Deposit a base bank guarantee	$ 500,000
Additional bank guarantee for drilling	$ 250,000
Accrued license costs			$ 0	$ 0
Bank guarantees to government		$ 1,179,000	1,179,000
Bank guarantees to others		90,000	90,000
Aggregate guarantee amount		1,269,000	$ 1,269,000
Foreign currency exchange rate risks, description			A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels (“NIS”). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar (“USD”), our primary reporting currency. During the period January 1, 2021 through September 30, 2021, the USD has fluctuated by approximately 0.4% against the NIS (the USD strengthened relative to the NIS). By contrast, during the period January 1, 2020 through December 31, 2020, the USD fluctuated by approximately 7.0% against the NIS (the USD weakened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.
Cash equivalents and short-term bank deposits		$ 5,833,000	$ 5,833,000
Weighted average annual interest rate		9.00%	11.00%

Subsequent Events (Details)

Subsequent Events (Details)	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent events description	(i)Approximately $4,378,000 was collected through the Company’s DSPP program during the period October 1, through November 10, 2021.